Vyvgart Hytrulo CIDP denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Imposes Step Therapy for Vyvgart Hytrulo in CIDP

Step therapy (also called "fail first") is one of the most common barriers to specialty biologics. Blue Cross Blue Shield plans typically require that patients with CIDP demonstrate a documented trial of one or more specified prior therapies before approving Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc). The required "steps" are usually drawn from established first-line and second-line CIDP treatments recognized in neurology guidelines. A step-therapy denial does not mean the drug is inappropriate — it means BCBS's records do not yet show that the required steps have been completed.

## Why This Denial Is Appealable

Step-therapy requirements are overridable when: (1) the patient has already tried and failed the required prior therapies, (2) prior therapies are contraindicated or clinically unsuitable, or (3) the patient's clinical condition requires the requested therapy without delay. Many states have enacted step-therapy override laws requiring insurers to grant exceptions on these grounds. Even without a state law, ACA §2719 and ERISA §503 require a full-and-fair review of any adverse benefit determination.

## Federal Appeal Framework

• Step-therapy override request: File this as the first step, often using the plan's own exception form, with documentation of prior therapy history or clinical contraindications.
• Internal appeal: If the override is denied, escalate to a formal internal appeal under ACA §2719 / ERISA §503.
• External review: A denied step-therapy override is subject to independent external review. File within the window on the denial notice (typically around four months from the final internal denial).
• State protections: Check whether your state has a step-therapy override statute — many require a decision within a defined timeframe and set specific override criteria.
• Expedited review: Request if the patient's condition is deteriorating and delay poses serious health risk.

## Documentation to Gather

1. Prior therapy history — for each therapy the BCBS policy lists as a required step, provide: the agent name, start date, end date, dose as documented in the chart, and the specific outcome (inadequate response with objective measures, adverse event details, or clinical rationale for unsuitability). 2. Current BCBS step-therapy criteria — download the plan's current policy to identify exactly which prior therapies are required and what constitutes adequate trial. 3. Neurologist's override letter — a detailed letter explaining why each required step has been completed, is contraindicated, or is otherwise clinically unsuitable for this patient. 4. Objective severity documentation — functional assessments and disease-severity measures from the chart demonstrating why the patient needs Vyvgart Hytrulo specifically. 5. FDA prescribing label — to confirm the approved indication and the clinical basis for the drug's use.

## Criteria-Mapping Structure

Create a step-by-step table: each required prior therapy listed in the BCBS policy in column one, the chart evidence of trial or contraindication in column two, and the documented outcome in column three. Obtain the required step list from the current BCBS published policy — not from memory or prior-year documents — as step requirements change with formulary updates.